Breaking News Instant updates and real-time market news.

GBT

Global Blood Therapeutics

$77.50

-0.57 (-0.73%)

, NVS

Novartis

$93.65

0.55 (0.59%)

12:25
12/17/19
12/17
12:25
12/17/19
12:25

Cantor Fitzgerald biotech analyst to hold an analyst/industry conference call

Biotech Analyst Young, along with Key Opinion Leader Dr. Vivien Sheehan, Asst Professor in Pediatrics-Hematology at Baylor College of Medicine, discuss the near-term and long-term uptake of Global Blood Therapeutics' Oxbryta, Adakvea (P-selectin antibody by Novartis) and Teva/Bristol-Myers Hydroxyurea in Sickle Cell Disease on an Analyst/Industry conference call to be held on December 17 at 1 pm.

GBT

Global Blood Therapeutics

$77.50

-0.57 (-0.73%)

NVS

Novartis

$93.65

0.55 (0.59%)

BMY

Bristol-Myers

$64.20

0.7 (1.10%)

TEVA

Teva

$9.73

-0.13 (-1.32%)

  • 17

    Dec

  • 17

    Dec

  • 18

    Dec

  • 26

    Feb

GBT Global Blood Therapeutics
$77.50

-0.57 (-0.73%)

12/17/19
PIPR
12/17/19
NO CHANGE
PIPR
Piper a buyer of Aimmune, Global Blood, Horizon into 2020 launches
Analysts at Piper Jaffray are buyers of Aimmune Therapeutics (AIMT), Global Blood Therapeutics (GBT) and Horizon Pharma (HZNP) into expected 2020 launches. Over the last five years, more launches have underperformed than outperformed, and the stock reactions have been largely proportionate to the level of under/over performance, the analysts tell investors in a research note. However, they point out that under the "somewhat rare circumstances" where performance has beaten expectations meaningfully, the stock reactions "can pay off handsomely." As such, Piper believes these three stocks can beat the "well entrenched biopharma default thesis to 'short the launch.'"
12/10/19
PIPR
12/10/19
NO CHANGE
Target $120
PIPR
Overweight
Global Blood Therapeutics price target raised to $120 from $95 at Piper Jaffray
Piper Jaffray analyst Danielle Brill raised her price target for Global Blood Therapeutics to $120 from $95 after speaking to a sickle cell disease key opinion leader. The stock closed Monday down $4.24 to $75.11. The analyst is "increasingly confident" in Oxbryta's launch and long-term trajectory, noting that the key opinion leader expects 10%-20% of his patients will go on drug within the first year of launch. Looking out five years from now, the leader anticipates that 40%-50% of the sickle cell disease population could be on drug, Brill tells investors in a research note. As such, she's "still pounding the table" on Global Blood shares and keeps an Overweight rating on the name.
11/26/19
RHCO
11/26/19
NO CHANGE
Target $110
RHCO
Buy
Global Blood Therapeutics price target raised to $110 from $100 at SunTrust
SunTrust analyst Joon Lee raised his price target on Global Blood Therapeutics to $110 and kept his Buy rating, adjusting his model after yesterday's FDA decision to approve Oxbryta, formerly voxeltor, for SCD on an accelerated basis and "significantly" ahead of the Feb 26th PDUFA. The analyst notes that the label is "rather broad and consistent" with the trial demographics and efficacy/safety results that the company disclosed previously. Lee adds that the early approval "speaks to the significance" of the drug's value proposition in SCD.
11/26/19
OPCO
11/26/19
NO CHANGE
Target $100
OPCO
Outperform
Global Blood price target raised to $100 from $94 at Oppenheimer
Oppenheimer analyst Mark Breidenbach raised his price target for Global Blood Therapeutics to $100 from $94 after Oxbryta received accelerated approval from the FDA, three months ahead of the action date. Oxbryta represents a new class of disease-modifying therapy, and could potentially become a therapeutic mainstay in sickle cell anemia, Breidenbach tells investors in a research note. Further, Oxbryta's "best-case" label includes adults and adolescents 12 years and older, adds the analyst. He keeps an Outperform rating on Global Blood shares.
NVS Novartis
$93.65

0.55 (0.59%)

12/16/19
EVER
12/16/19
DOWNGRADE
Target $381
EVER
In Line
Evercore downgrades Regeneron on Eylea risk from Beovu
Evercore ISI analyst Joshua Schimmer downgraded Regeneron Pharmaceuticals (REGN) to In Line from Outperform with an unchanged price target of $381. Early feedback on Novartis' (NVS) Beovu is stronger than expected, which creates risk of erosion for Regeneron's Eylea in 2020 and 2021, Schimmer tells investors in a research note. He now believes Eylea's erosion will be faster than anticipated and "dominate investor dialogue as investors check with specialists."
12/16/19
12/16/19
NO CHANGE

Novartis ends development of fevipiprant in asthma after Phase III failure
Novartis announced topline results from its pivotal global Phase III LUSTER-11and LUSTER-22studies exploring the efficacy and safety of the investigational oral, once-daily, DP2receptor antagonist fevipiprant. The pooled analyses of the LUSTER trials did not meet the clinically relevant threshold for reduction in rate of moderate -to-severe exacerbation compared to placebo over a 52-week treatment period for either of the doses. The studies included patients who had inadequately controlled moderate-to-severe asthma despite receiving inhaled mid-to-high dose corticosteroids and at least one additional controller. The totality of these results do not support further development of fevipiprant in asthma, Novartis said in a statement. "While the results of the LUSTER studies with fevipiprant are disappointing, they meaningfully contribute to our understanding of the DP2pathway in asthma. We are incredibly grateful to all the patients, their families and the investigators who participated in the studies and contributed greatly to this research," said John Tsai, Head Global Drug Development and Chief Medical Officer, Novartis.
12/06/19
CANT
12/06/19
INITIATION
Target $34
CANT
Overweight
Gossamer Bio initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Eliana Merle initiated coverage of Gossamer Bio (GOSS) with an Overweight rating and $34 price target. The analyst sees a "compelling" setup into 2020. While the Luster data from Novartis (NVS) has significant stock moving potential for Gossamer, with upside potential of 75%-100% versus downside of 25%-50%, GB002 for pulmonary arterial hypertension could be a $2B peak sales opportunity with potential de-risking in the first half of 2020 "that deserves more focus," Merle tells investors in a research note.
12/15/19
12/15/19
NO CHANGE

Jefferies gives European investors 'Christmas list of 20 stocks for 2020'
Analysts at Jefferies presented a European "Christmas list of 20 stocks for 2020." There are 10 large cap buys, five mid-cap buys and five stocks that the firm thinks will underperform. The list of buys are Amadeus IT Group (AMADY), Anglo American (NGLOY), Barclays (BCS), BP (BP), BT Group (BT), Carlsberg (CABGY), Demant (WILYY), E.ON (EONGY), Intermediate Capital, Intertek (IKTSY), Novartis (NVS), Persimmon (PSMMY), Puma (PUMSY), RSA Insurance (RSNAY) and Koninklijke Vopak (VOPKY). The five European stocks that Jefferies thinks will underperform in 2020 are Hammerson (HMSNF), NMC Health (NMHLY), Reckitt Benckiser (RBGLY), Renault (RNLSY) and Securitas.
BMY Bristol-Myers
$64.20

0.7 (1.10%)

12/13/19
ARGS
12/13/19
UPGRADE
Target $80
ARGS
Buy
Bristol-Myers upgraded to Buy from Hold at Argus
Argus analyst David Toung upgraded Bristol-Myers to Buy from Hold with an $80 price target.
12/13/19
ARGS
12/13/19
UPGRADE
Target $80
ARGS
Buy
Bristol-Myers upgraded to Buy from Hold at Argus
Argus analyst David Toung upgraded Bristol-Myers to Buy from Hold with an $80 price target. The analyst says his view on the progress of the company advancing the pipeline of assets combined with Celgene has improved, particularly with two Celgene drugs - Reblozyl and Inrebic - receiving FDA approval since the merger. While the company continues to face merger integration risks and financial risks around its leverage, Toung believes that the pipeline positives outweigh these factors.
12/13/19
12/13/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Snap (SNAP) upgraded to Outperform from Market Perform at JMP Securities with analyst Ronald Josey saying he is "incrementally confident" in Snap's ability to grow its user base, increase engagement, and improve overall monetization as the service attracts more advertisers and share of advertising budgets. 2. Ciena (CIEN) upgraded to Overweight from Neutral at Piper Jaffray with analyst Troy Jensen saying Ciena reported another strong quarter with October beating sales consensus estimates. 3. Bristol-Myers (BMY) upgraded to Buy from Hold at Argus with analyst David Toung saying his view on the progress of the company advancing the pipeline of assets combined with Celgene has improved, particularly with two Celgene drugs - Reblozyl and Inrebic - receiving FDA approval since the merger. 4. Bluebird Bio (BLUE) upgraded to Outperform from Perform at Oppenheimer with analyst Mark Breidenbach saying that given registration-enabling data for ide-cel in hand and undeniably positive updates for lentiglobin/Zynteglo presented at the American Society of Hematology meeting, he anticipates less headwind for bluebird heading into 2020. 5. NuVasive (NUVA) upgraded to Outperform from Market Perform at SVB Leerink with analyst Richard Newitter saying he raised his 2020-2021 sales and earnings forecasts above consensus, due to more bullish top-line growth assumptions, specifically in U.S. Spinal Hardware. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/10/19
PIPR
12/10/19
NO CHANGE
Target $85
PIPR
Neutral
Bluebird Bio ASH updates 'not enough' to alter Piper's Neutral stance
Piper Jaffray analyst Tyler Van Buren said the beta thal and sickle cell updates offered by Bluebird Bio (BLUE) at the ASH medical meeting were "solid as per usual," adding that "LentiGlobin continues to look like a cure for most patients." In terms of myeloma, he believes Bluebird and partner Bristol-Myers (BMY) are "prudent" in accelerating ide-cel development. While admitting he is "tempted to get more constructive at these levels," the ASH updates were "not enough" to alter his stance and he keeps a Neutral rating on Bluebird shares, as he believes "reasonable" estimates for bb2121 are already assumed in the stock price, Van Buren tells investors.
TEVA Teva
$9.73

-0.13 (-1.32%)

11/12/19
11/12/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Argo Group (ARGO) upgraded to Outperform from Market Perform at Keefe Bruyette with analyst Christopher Campbell saying he believes the company's "sizable" Q4 International reserve charge will restore balance sheet confidence and that new CEO Kevin Rehnberg's U.S. Operations outperformance can be replicated in its International segment. 2. Live Nation (LYV) upgraded to Outperform from In Line at Evercore ISI with analyst David Joyce saying he believes Live Nation shares have "pulled back needlessly" following its Q3 earnings results, and recommended taking advantage of the pullback. 3. Rent-A-Center (RCII) upgraded to Buy from Hold at Stifel with analyst John Baugh saying the recent pullback in the shares creates an attractive entry point. 4. Crowdstrike (CRWD) upgraded to Neutral from Sell at Goldman Sachs with analyst Heather Bellini she sees a more balanced risk/reward with the stock down 23% since her October 11 downgrade to Sell. 5. Teva (TEVA) upgraded to Neutral from Underweight at JPMorgan with analyst Christopher Schott citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/18/19
OPCO
11/18/19
NO CHANGE
Target $12
OPCO
Outperform
Teva may be positioned to sustain U.S. generic revenue base, says Oppenheimer
Oppenheimer analyst Esther Rajavelu reviewed Teva's U.S. generic trends, saying that based on her firm's analysis, compared to 2017, GtN discounts may have narrowed during 2019, a higher proportion of Teva's current portfolio competes with fewer manufacturers, and more 2019 launches are in markets with less than or equal to 2 competitors. Based on these metrics, Rajavelu says Teva may be better positioned to sustain its U.S. generic revenue base. She keeps an Outperform rating and $12 price target on the shares.
11/20/19
JEFF
11/20/19
NO CHANGE
Target $9
JEFF
Hold
Teva 'offered little' on progress toward opioids settlement, says Jefferies
Jefferies analyst David Steinberg said Teva CEO Kare Schultz has "largely delivered" on stabilizing Teva's financials over the past two years on the job, but opioid litigation has overwhelmed the fundamentals lately. After hosting investor meetings at the company's headquarters in Israel, Steinberg said Teva "offered little in the way of tangible progress" toward getting its proposed opioid settlement approved by all the relevant parties. Steinberg, who notes that there are still 46 state attorneys general that need to opt in, said he believes that "seems uncertain" to happen. Given the opioid litigation is "clouding an already uncertain future," Steinberg keeps a Hold rating and $9 price target on Teva shares, though he added that management believes that the market is just about at the price stabilization phase of the generic drug pricing cycle.
11/27/19
GABE
11/27/19
NO CHANGE
GABE
Buy
Teva shares should be bought on opioid suit headline weakness, says Gabelli
Gabelli analyst Kevin Kedra noted that Teva shares fell by 8% yesterday on press reports that the company, along with at least five others, had received grand jury subpoenas related to an investigation under the Controlled Substances Act. However, he recommends buying Teva on this weakness as he contends such an investigation "feels like a fishing expedition at this point in the opioid litigation saga" and he believes that the burden of proof required for a criminal case against Teva seems unlikely to be met given "how far manufacturers are from end users within the pharmaceutical supply chain." Kedra keeps a Buy rating on Teva shares, adding that he does not expect this previously-disclosed investigation to have a material impact given that the company is already facing thousands of opioid lawsuits.

TODAY'S FREE FLY STORIES

TLGT

Teligent

$0.40

-0.0025 (-0.62%)

15:53
01/18/20
01/18
15:53
01/18/20
15:53
Conference/Events
Teligent to hold a special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

AYTU

Aytu BioScience

$0.80

0.0014 (0.18%)

15:48
01/18/20
01/18
15:48
01/18/20
15:48
Conference/Events
Aytu BioScience to hold a special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

DVA

DaVita

$79.45

0.43 (0.54%)

15:32
01/18/20
01/18
15:32
01/18/20
15:32
Conference/Events
DaVita to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

TSM

TSMC

$58.58

-0.18 (-0.31%)

09:16
01/18/20
01/18
09:16
01/18/20
09:16
Periodicals
Taiwan tech stocks can ignore China's bluster for now, Barron's says »

China's government…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KKR

KKR

$31.20

0.7 (2.30%)

, APO

Apollo Global

$50.35

1.26 (2.57%)

09:03
01/18/20
01/18
09:03
01/18/20
09:03
Periodicals
KKR undervalued compared with peers, Barron's says »

KKR (KKR) gained 50% last…

KKR

KKR

$31.20

0.7 (2.30%)

APO

Apollo Global

$50.35

1.26 (2.57%)

ARES

Ares Management

$37.29

0.47 (1.28%)

BX

Blackstone

$60.79

0.62 (1.03%)

CG

Carlyle Group

$33.30

0.36 (1.09%)

HLNE

Hamilton Lane

$67.25

-0.02 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 30

    Jan

  • 31

    Jan

  • 31

    Jan

  • 04

    Feb

  • 04

    Feb

  • 05

    Feb

  • 13

    Feb

  • 17

    Feb

  • 26

    Feb

SPCE

Virgin Galactic

$15.65

0.685 (4.58%)

, TWNK

Hostess Brands

$14.03

0.02 (0.14%)

08:56
01/18/20
01/18
08:56
01/18/20
08:56
Periodicals
'Blank-check' companies hot on Wall Street, Barron's says »

More than a quarter of…

SPCE

Virgin Galactic

$15.65

0.685 (4.58%)

TWNK

Hostess Brands

$14.03

0.02 (0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 04

    Mar

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

, NFLX

Netflix

$339.56

0.89 (0.26%)

08:47
01/18/20
01/18
08:47
01/18/20
08:47
Periodicals
Peacock's pricing might be 'killer feature,' Barron's says »

This week, Peacock…

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

NFLX

Netflix

$339.56

0.89 (0.26%)

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$47.48

0.62 (1.32%)

GOOGL

Alphabet Class A

$1,479.12

29.29 (2.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 22

    Jan

  • 23

    Jan

  • 03

    Feb

  • 03

    Feb

  • 10

    Feb

JWN

Nordstrom

$40.34

-0.15 (-0.37%)

, WMT

Walmart

$114.93

-0.96 (-0.83%)

08:36
01/18/20
01/18
08:36
01/18/20
08:36
Periodicals
Casper IPO highlights tech's promise, troubles, Barron' says »

Mattresses have been…

JWN

Nordstrom

$40.34

-0.15 (-0.37%)

WMT

Walmart

$114.93

-0.96 (-0.83%)

CSPR

Casper Sleep

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 18

    Feb

BA

Boeing

$324.11

-7.89 (-2.38%)

, DDAIF

Daimler AG

$0.00

(0.00%)

08:12
01/18/20
01/18
08:12
01/18/20
08:12
On The Fly
Week in Review: How Trump's policies moved stocks »

Catch up on the top…

BA

Boeing

$324.11

-7.89 (-2.38%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$13.76

-0.14 (-1.01%)

VWAGY

Volkswagen

$0.00

(0.00%)

FSLR

First Solar

$53.51

-0.42 (-0.78%)

AAPL

Apple

$318.66

3.33 (1.06%)

DQ

Daqo New Energy

$53.61

-0.025 (-0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 29

    Jan

SPOT

Spotify

$148.20

-3.59 (-2.37%)

18:15
01/17/20
01/17
18:15
01/17/20
18:15
Periodicals
Spotify in talks to acquire The Ringer, WSJ reports »

Spotify is in discussions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

CE

Celanese

$117.54

-0.53 (-0.45%)

18:00
01/17/20
01/17
18:00
01/17/20
18:00
Hot Stocks
Celanese announces acetyl intermediates price increases »

Celanese Corporation will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

BYND

Beyond Meat

$109.20

-1.16 (-1.05%)

17:58
01/17/20
01/17
17:58
01/17/20
17:58
Periodicals
Beyond Meat rival gets green light in Canada, The Star says »

Impossible Foods, a maker…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBD

Diebold

$11.09

-0.49 (-4.23%)

17:42
01/17/20
01/17
17:42
01/17/20
17:42
Periodicals
Breaking Periodicals news story on Diebold »

Diebold Nixdorf divests…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IEF

iShares 7-10 Year Treasury Bond ETF

$111.28

-0.13 (-0.12%)

, SHY

iShares 1-3 Year Treasury Bond

$84.73

-0.005 (-0.01%)

17:32
01/17/20
01/17
17:32
01/17/20
17:32
General news
Weekly CFTC Commitment of Traders highlights »

2-YEAR U.S. TREASURY net…

IEF

iShares 7-10 Year Treasury Bond ETF

$111.28

-0.13 (-0.12%)

SHY

iShares 1-3 Year Treasury Bond

$84.73

-0.005 (-0.01%)

SPY

SPDR S&P 500 ETF Trust

$331.98

1.08 (0.33%)

SLV

iShares Silver Trust

$16.82

0.04 (0.24%)

GLD

SPDR Gold Shares

$146.59

0.29 (0.20%)

FXE

Euro Currency Trust

$105.10

-0.43 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UBSFY

Ubisoft

$0.00

(0.00%)

17:32
01/17/20
01/17
17:32
01/17/20
17:32
Periodicals
Ubisoft to restructure editorial team after difficult 2019, VGC reports »

Ubisoft intends to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 18

    Feb

IMVT

Immunovant

$17.04

-0.01 (-0.06%)

17:27
01/17/20
01/17
17:27
01/17/20
17:27
Syndicate
Breaking Syndicate news story on Immunovant »

Immunovant files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TBLT

ToughBuilt

$0.33

-0.0255 (-7.11%)

17:20
01/17/20
01/17
17:20
01/17/20
17:20
Syndicate
ToughBuilt files to sell common stock, no amount given »

Maxim acted as sole book…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYO

Myomo

$0.32

0.0062 (1.98%)

17:18
01/17/20
01/17
17:18
01/17/20
17:18
Conference/Events
Myomo to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

SRRA

Sierra Oncology

$0.40

-0.02 (-4.76%)

17:14
01/17/20
01/17
17:14
01/17/20
17:14
Conference/Events
Sierra Oncology to host virtual special shareholder meeting »

Virtual Special…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

SRNE

Sorrento Therapeutics

$4.26

-0.15 (-3.40%)

17:10
01/17/20
01/17
17:10
01/17/20
17:10
Syndicate
Breaking Syndicate news story on Sorrento Therapeutics »

Sorrento Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKER

Akers Biosciences

$3.45

-0.1 (-2.82%)

17:01
01/17/20
01/17
17:01
01/17/20
17:01
Hot Stocks
Akers Biosciences reaches settlement agreements on two derivative actions »

Akers Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECA

Encana

$4.09

-0.18 (-4.22%)

16:40
01/17/20
01/17
16:40
01/17/20
16:40
Hot Stocks
Encana receives court approval for reorganization »

Encana Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

MBRX

Moleculin Biotech

$0.96

0.0122 (1.29%)

16:38
01/17/20
01/17
16:38
01/17/20
16:38
Syndicate
Breaking Syndicate news story on Moleculin Biotech »

Moleculin Biotech files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VOD

Vodafone

$20.07

-0.225 (-1.11%)

, BT

BT Group

$0.00

(0.00%)

16:37
01/17/20
01/17
16:37
01/17/20
16:37
Periodicals
BT, Vodafone consider urging PM Johnson not to ban Huawei in U.K., Reuters says »

BT Group (BT) and…

VOD

Vodafone

$20.07

-0.225 (-1.11%)

BT

BT Group

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
01/17/20
01/17
16:30
01/17/20
16:30
Options
Preliminary option volume of 28.7M today »

Preliminary option volume…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.